Translation and validation

Tracy D. Zhang, Scott C. Kolbe, Leah C. Beauchamp, Ella K. Woodbridge, David I. Finkelstein, Emma L. Burrows. How Well Do Rodent Models of Parkinson’s Disease Recapitulate Early Non-Motor Phenotypes? A Systematic Review. Biomedicines. 2022;10(12):3026. doi:10.3390/biomedicines10123026

Simon Lohse. Scientific inertia in animal-based research in biomedicine. Studies in History and Philosophy of Science Part A. 2021;89:41-51. doi:10.1016/j.shpsa.2021.06.016

Désirée H. Veening-Griffioen, Guilherme S. Ferreira, Wouter P. C. Boon, et al. Tradition, not science, is the basis of animal model selection in translational and applied research. ALTEX. 2021;38(1):49-62. doi:10.14573/altex.2003301

Biotechnology Innovation Organization, Informa Pharma Intelligence, Quantitative Life Sciences. Clinical Development Success Rates and Contributing Factors 2011-2020.; 2021:34. https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf.

Hubert Dirven, Gunn E. Vist, Sricharan Bandhakavi, et al. Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review. Scientific Reports. 2021;11(1):6403. doi:10.1038/s41598-021-85708-2

Michael Balls. It’s Time to Include Harm to Humans in Harm–Benefit Analysis — But How to Do It, That is the Question. Alternatives to Laboratory Animals. 2021;49(5):182-196. doi:10.1177/02611929211062223

Dean G. Brown, Heike J. Wobst, Abhijeet Kapoor, Leslie A. Kenna, Noel Southall. Clinical development times for innovative drugs. Nature Reviews Drug Discovery. 2021;21(11):793-794. doi:10.1038/d41573-021-00190-9

Michael M. Webster, Christian Rutz. How STRANGE are your study animals?. Nature. 2020;582:337-340. doi:10.1038/d41586-020-01751-5

Pandora Pound, Merel Ritskes-Hoitinga. Can prospective systematic reviews of animal studies improve clinical translation?. Journal of Translational Medicine. 2020;18:15. doi:10.1186/s12967-019-02205-x

Stanley T. Parish, Michael Aschner, Warren Casey, et al. An evaluation framework for new approach methodologies (NAMs) for human health safety assessment. Regulatory Toxicology and Pharmacology. 2020;112:104592. doi:10.1016/j.yrtph.2020.104592